BNTX · BioNTech SE

BioNTech's Q1 2026 results reflect seasonal softness in COVID-19 vaccine demand, with revenues declining 35% year-over-year to €118.1 million primarily from lower sales in this segment, aligning with management's expectations. R&D expenses rose to €557.0 million (adjusted €527.1 million), driven by investments in priority oncology programs like pumitamig and gotistobart, costs from 2025 acquisitions of BioNTech China (formerly Biotheus) and CureVac, and an intangible asset impairment, partially offset by reduced COVID-19 collaboration costs with Pfizer. SG&A increased to €150.8 million due to commercial build-up and acquired operations. The resulting IFRS net loss widened to €531.9 million from €415.8 million last year, with adjusted net loss at €494.6 million. CEO Ugur Sahin emphasized oncology execution, noting five new pivotal pumitamig trials initiated with Bristol Myers Squibb in 2026 across TNBC, MSS-CRC, gastric, and NSCLC indications, plus six late-stage readouts expected this year. CFO Ramón Zapata highlighted disciplined capital allocation amid a €16.8 billion cash position. The company reaffirmed 2026 guidance anticipating lower COVID-19 revenues but stable BMS collaboration and pandemic preparedness contract income, while planning manufacturing consolidation at Idar-Oberstein, Marburg, Singapore, and CureVac sites to generate €500 million in annual savings by 2029 without disrupting supply. A $1.0 billion ADS repurchase program underscores confidence in long-term value creation toward a multi-product oncology portfolio by 2030.